SpeeDx and Nepean Hospital Awarded Federal Funding for Viral Respiratory Biomarker Test

SpeeDx and Nepean Hospital Awarded Federal Funding for Viral Respiratory Biomarker Test

SpeeDx in partnership with Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital Intensive Care Unit were awarded funding through the MTPConnect Biomedical Translation Bridge (BTB) program. Funds will support the commercialisation of a respiratory virus host response test – a rapid-response assay to enhance current COVID-19 management activities and future viral pandemic preparedness.

Utilising newly patented InSigniaTM technology that enhances the measurement of gene expression, the commercial test will be a rapid, high-throughput tool to support risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.

Read the press release